Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by University of Zurich.
Recruitment status was  Recruiting
Novartis Pharmaceuticals
Information provided by:
University of Zurich Identifier:
First received: March 14, 2011
Last updated: March 15, 2011
Last verified: March 2011

Test safety and efficacy and of a novel IL-13 AB in the treatment of perianal fistulas

  • Trial with medicinal product

Condition Intervention Phase
Crohn's Disease
Drug: QAX567
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • complete closure of fistula

Estimated Enrollment: 3
Study Start Date: January 2011
Estimated Study Completion Date: November 2012
Estimated Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria: - diagnosis of Crohn's disease > 6 month with fistula - at least 1 ineffective fistula treatment in the past

Exclusion criteria: - TNF a antibody treatment failed in the past

- planned surgery

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01316601

Contact: 01 Studienregister MasterAdmins +41 (0)44 255 11 11

Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Novartis Pharmaceuticals
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

No publications provided

Responsible Party: Rogler Gerhard, Prof. Dr., University Hospital Zurich, Gastroenterology & Hepatology Identifier: NCT01316601     History of Changes
Other Study ID Numbers: Novartis CQAX576
Study First Received: March 14, 2011
Last Updated: March 15, 2011
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Crohn Disease
Digestive System Diseases
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases processed this record on November 20, 2014